4.5 Editorial Material

Chronic obstructive pulmonary disease and comorbidities in heart failure: the next frontier of sodium-glucose co-transporter 2 inhibitors?

Journal

EUROPEAN JOURNAL OF HEART FAILURE
Volume 23, Issue 4, Pages 644-647

Publisher

WILEY
DOI: 10.1002/ejhf.2109

Keywords

-

Ask authors/readers for more resources

This article provides an in-depth analysis of the effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease.
This article refers to 'Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF' by P. Dewan et al., published in this issue on pages 632-643.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available